Metformin has been reported to reduce α-dicarbonyls, which are known to contribute to diabetic complications. It is unclear whether this is due to direct quenching of α-dicarbonyls or to an improvement in glycemic control. We therefore compared the effects of metformin versus repaglinide, an antihyperglycemic agent with an insulin-secreting mechanism, on the levels of the α-dicarbonyl 3-deoxyglucosone (3DG).
|Journal||European Journal of Endocrinology|
|Number of pages||9|
|Publication status||Published - 2011|
- Confidence Intervals
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents